Personalized medicine is one of the most promising applications of organoid technology. Patient-derived and induced pluripotent stem-cell-derived organoids allow researchers to study individual disease characteristics and treatment responses.

The market was valued at USD 1.68 billion in 2024 and is projected to reach approximately USD 17.21 billion by 2035 at a CAGR of 23.55%. Human tissue accounts for approximately 58% of the source segment, while iPSC-based models are among the fastest-growing categories.marketresearchfuture

Human-tissue organoids are valued because they can provide biologically relevant models for studying patient-specific disease. They are used in oncology, genetic disease, gastrointestinal disorders, and regenerative medicine.

Induced pluripotent stem cells can be reprogrammed into different cell types, offering flexibility for disease modeling and patient-specific research. Their use is growing as reprogramming technologies improve and researchers seek alternatives to some traditional models.

Pharmaceutical companies use organoids to test drug candidates across different disease subtypes. Research institutions and biotechnology companies are developing organoid biobanks, assays, and platforms.

Disease modeling is the fastest-growing application segment, while drug discovery remains the largest application. Regenerative medicine and toxicity testing also offer opportunities.

North America leads, followed by Europe and Asia-Pacific. Regulatory support, reduced reliance on animal testing, and improvements in 3D culture, microfluidics, and bioprinting are supporting expansion.

Key companies include Organovo, TissUse, InSphero, Mimetas, Reprocell, STEMCELL Technologies, Corning, and Hurel Corporation.

Read more: Organoids Market Size, Share, Trends

People Also Ask

Q1. Why are human tissue organoids important?
They can provide more physiologically relevant models for studying human disease, drug response, and personalized treatment.

Q2. Why are iPSC-derived organoids growing quickly?
iPSCs can be reprogrammed into different cell types and support flexible, patient-specific research.

Tags: human tissue organoids, iPSC organoids, personalized medicine, patient-derived models, regenerative medicine